Philip Mack

Title(s)Adjunct Professor, Cancer Center
SchoolUniversity of California, Davis
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Hypoxia-induced Proteins as Lung Cancer Biomarkers
    NIH R01CA107228Sep 1, 2005 - Aug 31, 2008
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clin Cancer Res. 2022 09 01; 28(17):3752-3760. Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. PMID: 35713632; PMCID: PMC9444942.
      View in: PubMed   Mentions:    Fields:    
    2. A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer Chemother Pharmacol. 2022 09; 90(3):217-228. Chen JA, Huynh JC, Wu CY, Yu AM, Matsukuma K, Semrad TJ, Gandara DR, Li T, Riess JW, Tam K, Mack PC, Martinez A, Mahaffey N, Kelly KL, Kim EJ. PMID: 35907014; PMCID: PMC9402746.
      View in: PubMed   Mentions:    Fields:    
    3. Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization. J Clin Oncol. 2022 Nov 20; 40(33):3787-3789. Mack PC, Hirsch FR, Bunn PA, Minna JD. PMID: 35759731; PMCID: PMC9671753.
      View in: PubMed   Mentions:    Fields:    
    4. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. Oncologist. 2022 06 08; 27(6):476-486. Mack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, Rossi M, Ai-Kateb H, O'Connell T, Hantash FM, Oh WK, Newman S, Schadt EE, Chen R, Hirsch FR. PMID: 35298662; PMCID: PMC9177106.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022 Jun 02; 41(1):186. de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. PMID: 35650597; PMCID: PMC9161571.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. Cancer Cell. 2022 06 13; 40(6):575-577. Mack PC, Gomez JE, Rodilla AM, Carreño JM, Hsu CY, Rolfo C, Meshulami N, Moore A, Brody RI, King JC, Treatman J, Lee S, Raskin A, Srivastava K, Gleason CR, de Miguel-Perez D, PARIS/PSP study group, Tcheou J, Bielak D, Acharya R, Gerber DE, Rohs N, Henschke CI, Yankelevitz DF, Simon V, Minna JD, Bunn PA, García-Sastre A, Krammer F, Shyr Y, Hirsch FR. PMID: 35504289; PMCID: PMC9020481.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    7. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. J Thorac Oncol. 2022 02; 17(2):214-227. Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA, Minna JD, Hirsch FR. PMID: 34774792; PMCID: PMC8579698.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    8. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clin Lung Cancer. 2022 01; 23(1):60-71. Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. PMID: 34753703; PMCID: PMC8766941.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    9. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1368-1377. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 34264316; PMCID: PMC8283667.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    10. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021 08; 9(8). Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. PMID: 34429332; PMCID: PMC8386207.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    11. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 10; 16(10):1647-1662. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. PMID: 34246791.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    12. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 11; 22(6):541-548. Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN. PMID: 34140248; PMCID: PMC9239707.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer. 2021 Apr 21; 21(1):441. Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC, Liu JJ, Schadt EE, Chen R, Li SD. PMID: 33882890; PMCID: PMC8059160.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    14. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing. J Mol Diagn. 2021 05; 23(5):507-520. Veluswamy R, Mack PC, Houldsworth J, Elkhouly E, Hirsch FR. PMID: 33618059.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    15. Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 1. McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. PMID: 34036220; PMCID: PMC8140807.
      View in: PubMed   Mentions: 3     Fields:    
    16. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 05; 22(3):187-194.e1. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. PMID: 33583720; PMCID: PMC8637652.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    17. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. PMID: 33125909; PMCID: PMC8109255.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    18. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021 05; 22(3):170-177. Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. PMID: 33221175; PMCID: PMC8044254.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    19. Ethnic difference in lung cancer: an important issue in a globalized society. J Thorac Dis. 2020 Jul; 12(7):3774-3775. Kawaguchi T, Mack PC. PMID: 32802456; PMCID: PMC7399403.
      View in: PubMed   Mentions: 1  
    20. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Cancer. 2020 07 15; 126(14):3219-3228. Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR. PMID: 32365229; PMCID: PMC7383626.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    21. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Kidney Cancer. 2019 Aug 07; 3(2):111-118. Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW. PMID: 31763512; PMCID: PMC6864417.
      View in: PubMed   Mentions: 2  
    22. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852. Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. PMID: 31195180; PMCID: PMC6901020.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    23. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807. Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. PMID: 31152080; PMCID: PMC6738301.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    24. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273; PMCID: PMC6421302.
      View in: PubMed   Mentions: 11  
    25. Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Transl Oncol. 2019 Apr; 12(4):683-692. Duan Z, Chinn D, Tu MJ, Zhang QY, Huynh J, Chen J, Mack P, Yu AM, Kim EJ. PMID: 30844579; PMCID: PMC6402293.
      View in: PubMed   Mentions: 6  
    26. Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048. Kidney Cancer. 2019 Feb 05; 3(1):51-61. Semrad TJ, Groshen S, Luo C, Pal S, Vaishampayan U, Joshi M, Quinn DI, Mack PC, Gandara DR, Lara PN. PMID: 30854497; PMCID: PMC6400131.
      View in: PubMed   Mentions: 3  
    27. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018 10; 13(10):1560-1568. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. PMID: 29981927; PMCID: PMC6764748.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    28. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst. 2018 07 01; 110(7):734-742. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB. PMID: 29346580; PMCID: PMC6037104.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    29. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 09; 13(9):1248-1268. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. PMID: 29885479.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    30. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018 08 01; 24(15):3528-3538. Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. PMID: 29776953.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    31. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888. Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM. PMID: 29801011; PMCID: PMC6583489.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    32. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treat Res Commun. 2018; 16:18-23. Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. PMID: 31298998; PMCID: PMC6628720.
      View in: PubMed   Mentions: 2     Fields:    
    33. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. PMID: 29520435; PMCID: PMC6330274.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    34. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 05; 17(5):885-896. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE. PMID: 29483211; PMCID: PMC5932243.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    35. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 01; 19(1):101-114. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. PMID: 29169877; PMCID: PMC5847342.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    36. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415; PMCID: PMC5709185.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCells
    37. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 01; 19(1):84-92. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. PMID: 28801183; PMCID: PMC5748264.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    38. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 12; 15(6):635-641. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. PMID: 28579151; PMCID: PMC5734863.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. PMID: 28736761; PMCID: PMC5519297.
      View in: PubMed   Mentions: 10     Fields:    
    40. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. PMID: 28082049.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May; 18(3):281-285. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. PMID: 28038979; PMCID: PMC5837026.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    42. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. PMID: 27229180.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    43. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. PMID: 26725184; PMCID: PMC4775366.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    44. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. PMID: 26498504; PMCID: PMC4789142.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    45. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689; PMCID: PMC4734742.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    46. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. Gandara DR, Lara PN, Mack PC. PMID: 26215942.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    47. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072; PMCID: PMC4592395.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    48. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther. 2015 May; 97(5):488-91. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. PMID: 25676724.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    49. Plasma-based tumor genetics for monitoring disease progression: what can we learn from a tube of blood? J Thorac Oncol. 2015 Apr; 10(4):546-7. Mack PC. PMID: 25789830; PMCID: PMC4573951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. PMID: 25838158; PMCID: PMC4586173.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    51. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. PMID: 25680375; PMCID: PMC4654466.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    52. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. PMID: 25611229; PMCID: PMC4304604.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    53. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. PMID: 25703100; PMCID: PMC4497941.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    54. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. PMID: 25490004; PMCID: PMC4320001.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    55. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. Holland WS, Chinn DC, Lara PN, Gandara DR, Mack PC. PMID: 25323938; PMCID: PMC4562434.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    56. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. PMID: 25219358; PMCID: PMC4323674.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    57. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. PMID: 25091263; PMCID: PMC4318776.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    58. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. PMID: 25002722; PMCID: PMC4121504.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    59. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol. 2014 Jul; 140(7):1137-49. Chinn DC, Holland WS, Mack PC. PMID: 24756365; PMCID: PMC4565522.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    60. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 2014 Aug 01; 120(15):2343-51. Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR. PMID: 24752945; PMCID: PMC4140446.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    61. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN, Mack PC, David EA. PMID: 24746995.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    62. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. PMID: 24616308; PMCID: PMC3970171.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCellsCTClinical Trials
    63. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. PMID: 24565955; PMCID: PMC3982883.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    64. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. PMID: 24189513; PMCID: PMC4072123.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    65. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Lung Cancer. 2014 Feb; 83(2):163-7. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR. PMID: 24331409.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    66. Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer. 2014 Apr; 12(2):74-9. Twardowski PW, Mack PC, Lara PN. PMID: 24629521.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    67. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. PMID: 24176733; PMCID: PMC4586161.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    68. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. PMID: 24013936; PMCID: PMC4562389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    69. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. PMID: 23910067; PMCID: PMC4122504.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. PMID: 23871417; PMCID: PMC4277263.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    71. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR. PMID: 23470290.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    72. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10; 31(8):1039-49. Li T, Kung HJ, Mack PC, Gandara DR. PMID: 23401433; PMCID: PMC3589700.
      View in: PubMed   Mentions: 203     Fields:    Translation:Humans
    73. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. Mack PC, Gandara DR, Lara PN. PMID: 23253224.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. PMID: 22677432; PMCID: PMC4049356.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    75. The Role of mTOR Inhibitors and P13K Pathway Blockade in RCC. . 2012 Jan 1; 209-223. Choueiri CM, Mack MP. .
      View in: Publisher Site   Mentions:
    76. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 2012 Jan; 7(1):34-9. Mahaffey CM, Mahaffey NC, Holland W, Zhang H, Gandara DR, Mack PC, Forman HJ. PMID: 22089114; PMCID: PMC3241903.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    77. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. Mol Cancer Ther. 2012 Mar; 11(3):616-28. Wilson PM, LaBonte MJ, Lenz HJ, Mack PC, Ladner RD. PMID: 22172489.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    78. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. PMID: 21892109; PMCID: PMC3219834.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    79. Fibroblast growth factor signaling in non-small-cell lung cancer. Clin Lung Cancer. 2012 Mar; 13(2):90-5. Semrad TJ, Mack PC. PMID: 21959109.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    80. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2012 Jun 01; 130(11):2693-702. Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP. PMID: 21792888.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    81. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer. 2012 Jun; 58(6):885-90. Chinn DC, Holland WS, Yoon JM, Zwerdling T, Mack PC. PMID: 21796766.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    82. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr; 23(4):1023-9. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. PMID: 21778300.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    83. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN. PMID: 21644050; PMCID: PMC4562405.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    84. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. Rothschild SI, Gautschi O, Lara PN, Mack PC, Gandara DR. PMID: 21119513.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    85. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. PMID: 21273177; PMCID: PMC3777729.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    86. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. Gandara DR, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, Danenberg KD. PMID: 20975603.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    87. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. PMID: 20967484; PMCID: PMC3277821.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    88. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. PMID: 20921467; PMCID: PMC3020704.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    89. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. PMID: 20559150; PMCID: PMC2911495.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    90. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. PMID: 20484019; PMCID: PMC2898710.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    91. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 20681067; PMCID: PMC6136060.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. PMID: 20148348; PMCID: PMC4559347.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    93. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR. PMID: 19839922.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    94. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara DR. PMID: 19884861.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    95. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. PMID: 19884559; PMCID: PMC2793000.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    96. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 19900855.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    97. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol. 2009 Oct; 32(5):453-9. Van Veldhuizen PJ, Hussey M, Lara PN, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. PMID: 19487915; PMCID: PMC3394591.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    98. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol. 2009 Sep; 4(9):1104-10. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack PC. PMID: 19620934.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    99. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. PMID: 19470925; PMCID: PMC2717760.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    100. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. Gandara DR, Lara PN, Mack P, Scagliotti G. PMID: 19443333.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    101. GCP, a genistein-rich compound, inhibits proliferation and induces apoptosis in lymphoma cell lines. Leuk Res. 2010 Jan; 34(1):69-76. McCall JL, Burich RA, Mack PC. PMID: 19394691.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    102. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic Biol Med. 2009 Jun 15; 46(12):1650-7. Mahaffey CM, Zhang H, Rinna A, Holland W, Mack PC, Forman HJ. PMID: 19345732; PMCID: PMC2692873.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    103. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. PMID: 19240653; PMCID: PMC2716757.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    104. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21. Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. PMID: 19307945.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    105. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. Sangha R, Lara PN, Mack PC, Gandara DR. PMID: 19532012.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    106. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. PMID: 19169683.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCTClinical Trials
    107. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR, SWOG. PMID: 18779603; PMCID: PMC2653139.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    108. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008 Sep; 3(9):1026-31. Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. PMID: 18758306; PMCID: PMC3523698.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    109. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU Int. 2008 Nov; 102(10):1458-66. Burich RA, Holland WS, Vinall RL, Tepper C, White RW, Mack PC. PMID: 18565171.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    110. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res. 2008 May; 6(5):808-18. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, deVere White RW. PMID: 18505925.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    111. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. PMID: 18381431.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    112. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. PMID: 18347165.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansAnimals
    113. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. Sangha R, Lara PN, Mack P, Gandara DR. PMID: 19419929.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    114. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions. Clin Lung Cancer. 2008; 9 Suppl 3:S129-38. Gautschi O, Mack PC, Davies AM, Jablons DM, Rosell R, Gandara DR. PMID: 19419927.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    115. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. Mahaffey CM, Davies AM, Lara PN, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR. PMID: 18186959.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    116. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 01; 25(22):3296-301. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED, Southwest Oncology Group. PMID: 17664477.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    117. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. Davies AM, Lara PN, Mack PC, Gandara DR. PMID: 17671158.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    118. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clin Lung Cancer. 2007 Jul; 8(7):420-4. Ho C, Davies A, Mack P, Gandara D. PMID: 17681094.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    119. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4):331-9. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN. PMID: 17471291.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    120. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 2007 Sep 08; 254(2):265-73. Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC. PMID: 17449174.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    121. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007 Apr 01; 67(5):521-35. Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW. PMID: 17252539.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    122. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. PMID: 17382026.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    123. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. PMID: 17409985.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    124. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. Gautschi O, Mack PC, Davies AM, Lara PN, Gandara DR. PMID: 17026809.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    125. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR. PMID: 16800963.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    126. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. PMID: 16384543.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    127. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. Davies AM, Lara PN, Mack PC, Gumerlock PH, Bold RJ, Gandara DR. PMID: 16250929.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    128. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. Lara PN, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR. PMID: 16250931.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    129. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. PMID: 16000614.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    130. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. Lara PN, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 15958629.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    131. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat Res. 2004 Dec; 162(6):623-34. Mack PC, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z. PMID: 15548112.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    132. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. PMID: 15476595.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    133. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate. 2004 Aug 01; 60(3):257-71. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW. PMID: 15176055.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    134. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. PMID: 19777702.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    135. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. PMID: 14981579.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    136. Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2004; 7(4):321-6. Gandour-Edwards R, Mack PC, Devere-White RW, Gumerlock PH. PMID: 15314639.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    137. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR, California Cancer Consortium. PMID: 14581348.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    138. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. PMID: 14555506.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    139. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. PMID: 12867067.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    140. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. Davies AM, Lara PN, Mack PC, Gandara DR. PMID: 12667118.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    141. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. PMID: 12721762.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    142. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. Davies AM, Gandara DR, Lara PN, Mack PC, Lau DH, Gumerlock PH. PMID: 14720340.
      View in: PubMed   Mentions: 4     Fields:    
    143. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. PMID: 11894020.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    144. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001 Dec; 34 Suppl 3:S75-80. Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. PMID: 11740998.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    145. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. PMID: 11488520.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    146. Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm. 2001 Jun; 16(3):213-25. Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ. PMID: 11471486.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    147. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res. 1999 Sep; 5(9):2596-604. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH. PMID: 10499638.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    148. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate. 1999 Jan 01; 38(1):40-5. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, Pretlow TG, Tricoli JV. PMID: 9973108.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    149. Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate. 1998 Feb 01; 34(2):145-51. Mack PC, Chi SG, Meyers FJ, Stewart SL, deVere White RW, Gumerlock PH. PMID: 9465946.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    150. Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth. Biochem Mol Med. 1997 Apr; 60(2):108-15. Morris G, DeNardo SJ, DeNardo GL, Leshchinsky T, Wu B, Mack PC, Winthrop MD, Gumerlock PH. PMID: 9169090.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    151. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res. 1995 Dec 01; 55(23 Suppl):5837s-5841s. DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere White RW, DeNardo GL. PMID: 7493356.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    Philip's Networks
    Concepts (481)
    Derived automatically from this person's publications.
    _
    Co-Authors (61)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _